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Abstract 
 
Percutaneous coronary intervention with stent placement is widely used to achieve 
revascularization of the myocardium, especially in acute coronary syndrome. There is 
increasing number of reports published concerning stent thrombosis both in bare 
metal stents as in drug eluting stents. According to the newest ACC/AHA/SCAI 
2007th guidelines, bare-metal stent or balloon angioplasty is recommended as an 
optimal solution if surgery is to be performed in 6–12 months time after stent 
placement. We present a case of a 56-year-old male with colon carcinoma who 
suffered from post-operational myocardial infarction due to bare metal stent 
thrombosis, while the drug eluting stent remained patent. Currently, in our opinion, 
high level evidence is lacking in the literature in support for recommendations 
published in current ACC, AHA and SCAI 2007th guidelines regarding the choice of 
stent, antiaggregation and anticoagulation therapy. This case, together with others 
previously published suggests a need for development of an applicable strategy for 
selection and treatment of patients with increased perioperative risk of in-stent 
thrombosis in order to ensure optimal medical treatment. 
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1. Background 
 
Percutaneous coronary intervention (PCI) with stent placement is widely used to 
achieve revascularization of the myocardium, especially in acute coronary syndrome 
[1]. There are an increasing number of patients treated with PCI with stent 
implantation subsequently requiring non-cardiac surgery [2]. The issue of 
antiaggregation and anticoagulation therapy in the coronary artery patients with stent 
implantation requiring non-cardiac surgery is controversial [2]. According to the 
newest ACC/AHA guidelines, bare-metal stent (BMS) or balloon angioplasty is 
recommended as an optimal solution if surgery is to be performed in 6–12 months 
time after stent placement [3]. Furthermore, same recommendations were proposed 
by some authors published in this journal [4]. We present a unique case of a patient 
with colon carcinoma who suffered from post-operational myocardial infarction due to 
BMS thrombosis after discontinuation of an antiplatelet therapy and introduction of 
low-molecular weight heparin prior to colorectal cancer surgery, while the drug eluting 
stent (DES) remained patent. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2. Case presentation 
 
We present a case of a 56-year-old male with a positive family history of coronary 
artery disease and colonic cancer, who was admitted to hospital in 1996, for elective 
coronarography due to angina pectoris. Significant circular narrowing of proximal left 
anterior descending artery (LAD) and nonsignificant atherosclerotic changes in other 
coronary arteries were found. PCI of LADwas performedwithout coronary stent 
placement. Following this  procedure, the patient was asymptomatic with repeatedly 
negative stress testing. In November 2006, he was again admitted to hospital 
because of an unstable angina pectoris. Significant stenosis of proximal LAD (in the 
segment of previous PCI) was found, combined with occlusion of proximal left 
circumflex artery (LCx) with significant stenosis of firstmarginal branch (OM1). 
Primary PCIwith stent implantation was performed. Baremetal stents were placed in a 
proximal segment of LAD and proximal segment of OM1. In the previously occluded 
LCx, DES was implanted. After the PCI patient had no chest pain and was 
discharged from hospital in an excellent condition. Sixmonths later, in the same 
patient a colorectal carcinoma (Dukes C) was diagnosed and elective operation was 
planned for May 2007. Because of indicated abdominal surgery a dual 
antiaggregation therapy (aspirin+ clopidogrel) was discontinued 5 days prior, and 
low-molecular weight heparin (enoxaparine 0.5 mg/kg) was started as requested by 
anesthesiologist and attending surgeon. The planned resection of descending colon 
was preformed successfully and patient was admitted to the surgical intensive care 
unit (ICU). Five hours after admittance in the ICU a patient developed myocardial 
infarction with ST segment elevation (STEMI) of the anteroseptal region.Our 
patientwas admitted to cardiac catheterization laboratory for urgent PCI. He received 
600 mg of clopidogrel before procedure, heparin and eptifibatide infusion during and 
after PCI procedure. Coronary angiography showed a thrombotic occlusion of BMS in 
proximal LAD and fairly patent DES and other BMS in LCx/OM1 (Fig. 1). Occluded 
segment was dilated with a balloon and TIMI III flow was established (Fig. 2). 
Immediately after procedure, patient had chest pain relief and rapid resolution of 
STsegment elevation, and no signs of a significant hemorrhage. He was discharged 
from hospital 9 days later on a dual antiplatelet therapy. 
 
Fig. 1. Coronarography: occluded LAD with thrombi in previously implanted BMS (A). 
DES in ACx is fairly patent (B). 
 
 
 
 
 
  
 
Fig. 2. Coronarography: TIMI 3 flow in LAD after eptifibatide bolus and ballooning (A). 
 
 
3. Discussion 
An increasing number of patients have history of recent coronary stent implantation 
and may subsequently require noncardiac surgery [2]. According to some authors a 
discontinuation of antiplatelet therapy prior to surgery is suggested to prevent major 
bleeding [5]. This brings to a high risk of in-stent thrombosis resulting in myocardial 
infarction with catastrophic outcomes in such patients [5]. Since DES have been 
introduced, they have been proven at least as safe as BMS in the follow-up period up 
to 12 months, with tremendous improvement in issue of restenosis [6]. However 
some studies, especially Basket Late Study, showed that late stent thrombosis 
(resulting in acute myocardial infarction/death) is 2–3 times more frequent among 
patients who had received DES than among those who had received BMS. It is 
considered that is mostly due to postponed reendothelisation of DES [7]. Therefore, 
new ACC, AHA and SCAI 2007th updated guidelines for PCI recommended use of 
BMS or balloon angioplasty for patients that may need noncardiac surgery within 6–
12 months [3]. The same recommendation is preferred by authors published in this 
journal [4]. 
We present a unique case of late bare metal stent thrombosis in a patient operated 
for colorectal carcinoma, while drug eluting stent remained patent. This case together 
with other similar which were published [8], suggests that application of these 
guidelines is hardly acceptable in patients with an aggressive malignancy. The risk of 
in-stent thrombosis and myocardial infarction in this group of patients is 
not only due to whether the stent is BMS or DES, but also because of acute surgical 
stress, inflammatory response andblood loss with haemodilution [9]. Furthermore, the 
abbreviated coagulationmechanism in patients with malignancies combined with 
discontinuation of antiaggregation therapy brings additional risk of stent thrombosis 
[10]. 
We would suggest a development of an applicable strategy for selection of patients 
with increased risk of in-stent thrombosis in other to reduce potentially catastrophic 
post-operative complications and to ensure development of optimal therapy protocols 
in the setting of non-cardiac surgery. 
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